Almost half of U.S. adults with diabetes did not meet recommended goals for diabetes care, despite improvements in controlling risk factors and adhering to preventive practices from 1999 to 2010, a study concluded.
Researchers have developed a new Web-based calculator that predicts short-term mortality risk in patients with type 2 diabetes.
Aspirin showed no cardiovascular benefit and may have been associated with worse outcomes in a recent study of patients with type 2 diabetes.
Sitagliptin was associated with similar rates of hospital admission and mortality as other glucose-lowering drugs, according to a recent study of patients with type 2 diabetes.
Consequences of hypoglycemia and strategies to prevent this condition in patients with diabetes were discussed in a recent consensus statement from the American Diabetes Association (ADA) and The Endocrine Society.
Metformin appears to be a safe option for glycemic control in heart failure patients, according to a recent meta-analysis.
The growing problem of diabetic retinopathy in young people and the need for response by primary care clinicians are discussed in the April ACP Internist.
A meta-analysis included 67 randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo or other oral antidiabetic agents.
A multicenter randomized controlled trial of Chinese patients with type 2 diabetes and coronary artery disease found that metformin reduced cardiovascular events more than glipizide at 5 years.
Some key messages should be given to patients about avoiding and treating hypoglycemia.
Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were approved by the FDA to improve blood glucose control in adults with type 2 diabetes, along with diet and exercise.
The FDA is investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes.